for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

FACTBOX-Moderna's mRNA coronavirus vaccine

 (Adds regulatory decision and additional doses for Britain)
    Jan 8 (Reuters) - Britain's medical regulator on Friday approved U.S. drugmaker Moderna Inc's
COVID-19 vaccine candidate for emergency use, making it the third vaccine to receive
authorization in the country. Earlier this week, the European Union's drug watchdog authorized
emergency use of the Moderna vaccine.
    On Tuesday, Israel became the first country outside North America to grant authorization to
Moderna's vaccine. The United States and Canada have already started rolling out the two-dose
vaccine.
    Below are more details on Moderna's vaccine: 
    
    VACCINE TECHNOLOGY
    - The vaccine, called mRNA-1273, is based on messenger RNA (mRNA) technology, which relies on
synthetic genes that can be generated and manufactured in weeks, and produced at scale more
rapidly than conventional vaccines. 
    
    - Pfizer's mRNA vaccine for COVID-19 was the first authorization of any treatment developed
using the technology.
    
    - Other firms using mRNA technology for developing COVID-19 vaccines include Germany's
Curevac and U.S. biotech firm Arcturus Therapeutics Holdings Inc.    
    
    - Moderna's vaccine can be stored for up to six months at -20 degrees Celsius, though it is
expected to be stable for 30 days at normal fridge temperature of 2 to 8 degrees Celsius (36
degrees Fahrenheit to 46 degrees Fahrenheit). Those are less onerous requirements than Pfizer's,
which must be stored at ultra-cold temperatures of -70 degrees Celsius, but can last in normal
refrigeration for up to five days, or 15 in a thermal shipping box.  
    
    TRIALS
    - The vaccine was shown to be nearly 95% effective, with no serious safety concerns in a
late-stage study.
    
    - Moderna was among the first to conduct COVID-19 vaccine human trials, starting in March.
Its late-stage 30,000 participant testing began on July 27 in the United States. It finished
enrolling participants in October.
    
    - The company slowed enrollment in September to increase the diversity of the trial
population. It ultimately enrolled 3,000 Black American participants and more than 6,000 Hispanic
participants.
    
    - The vaccine candidate is being tested at 100 clinical research sites in the United States.
    
    - Moderna's U.S. trial was the first under the government's Operation Warp Speed program and
is funded by Biomedical Advanced Research and Development Authority and National Institute of
Allergy and Infectious Diseases, part of the National Institutes of Health.
    
MODERNA SUPPLY DEALS
(most recent first)          
 REGION        DOSES                 FUNDING         EXPECTED DELIVERIES      FURTHER
 U.S.          200 mln               $1.53 bln       200 mln (18 mln in                   
                                                     2020, 100 mln in Q1      
                                                     2021 and rest in Q2)     
 EU            160 mln               Unspecified     Early 2021                           
 Canada        40 mln                Unspecified     Up to 168,000 doses                  
                                                     before end of December   
 Japan         50 mln doses, to be   Unspecified     H1 of 2021                           
               distributed by                                                 
               Takeda                                                         
 South Korea   40 mln doses          Unspecified     Delivery to begin in                 
                                                     May                      
 Israel        6 mln                 Unspecified     Delivery to begin in                 
                                                     March                    
 Qatar         Unspecified           Unspecified     As soon as vaccine is                
                                                     approved and released    
 Singapore     Unspecified           Unspecified     Unspecified                          
 UK            17 mln                Unspecified     Spring 2021                          
 Switzerland   7.5 mln               Unspecified     Unspecified (Source: Reuters reporting, press releases, clinical trial registers)    

 (Reporting by Manas Mishra, Vishwadha Chander and Mrinalika Roy in Bengaluru; Editing by
Caroline Humer, Edwina Gibbs, Ramakrishnan M., David Gregorio, Shinjini Ganguli, Anil D'Silva and
Maju Samuel)
  
for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up